In the randomized phase III BELLE-2 study, which examined the efficacy of the PI3K inhibitor buparlisib in patients with hormone receptor-positive, HER2 negative breast cancer, PIK3CA mutation in tumor tissue and ctDNA was investigated [37]. Here, PIK3CA is linked to neoplasm.